company background image
CYBN logo

Cybin NYSEAM:CYBN Stock Report

Last Price

US$0.41

Market Cap

US$326.8m

7D

1.5%

1Y

8.8%

Updated

28 Mar, 2024

Data

Company Financials +

Cybin Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cybin
Historical stock prices
Current Share PriceUS$0.41
52 Week HighUS$0.74
52 Week LowUS$0.21
Beta0.93
1 Month Change18.82%
3 Month Change0.85%
1 Year Change8.82%
3 Year Change-63.41%
5 Year Changen/a
Change since IPO-40.40%

Recent News & Updates

Recent updates

Shareholder Returns

CYBNUS PharmaceuticalsUS Market
7D1.5%1.2%0.4%
1Y8.8%25.8%28.8%

Return vs Industry: CYBN underperformed the US Pharmaceuticals industry which returned 25.8% over the past year.

Return vs Market: CYBN underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is CYBN's price volatile compared to industry and market?
CYBN volatility
CYBN Average Weekly Movement10.9%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CYBN's share price has been volatile over the past 3 months.

Volatility Over Time: CYBN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a50Doug Drysdalehttps://www.cybin.com

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine.

Cybin Inc. Fundamentals Summary

How do Cybin's earnings and revenue compare to its market cap?
CYBN fundamental statistics
Market capUS$326.82m
Earnings (TTM)-US$52.02m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CYBN income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$70.45m
Earnings-CA$70.45m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.093
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CYBN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.